Thursday, January 26, 2023 | Back issues
Courthouse News Service Courthouse News Service

Courthouse News Top Download

Allergan faces a federal class action from shareholders over the drugmaker’s 41 percent stock drop, from $319.47 in 2015 to $188.82 last month, upon news that it could face criminal charges for colluding to fix the prices of generic pharmaceuticals.

NEWARK, N.J. – Allergan faces a federal class action from shareholders over the drugmaker’s 41 percent stock drop, from $319.47 in 2015 to $188.82 last month, upon news that it could face criminal charges for colluding to fix the prices of generic pharmaceuticals.

USDC New Jersey

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading
Loading...